While AbbVie Inc. racks up settlement agreements with Humira (adalimumab) biosimilar makers, Boehringer Ingelheim GMBH is continuing efforts to invalidate AbbVie's patents by claiming they were obtained to improperly delay biosimilar competition.
Momenta Pharmaceuticals Inc. became the sixth company to ink a settlement agreement with AbbVie, which will enable it to...





